Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30379
Case Study: Oncological Management of a Patient with Papillary Thyroid Cancer

Authors: A. Taqaddas

Abstract:

The following case study presents the management of stage III Differentiated Thyroid Cancer (DTC) patient in an NHS hospital in London, UK during period of 2004-2005.

Keywords: Thyroid Cancer, papillary, Differentiated Thyroid Cancer, Oncological Management, Stage III

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1096239

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 2721

References:


[1] S. Sherman, "Thyroid Carcinoma,” The Lancet, 361, 2003, 501-511
[2] Cancer Research UK, "Thyroid Cancer Incidence statistics,” 2013. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/ types/thyroid/incidence/uk-thyroid-cancer-incidence-statistics#geog. (Accessed 28/09/2014).
[3] O. Gimm, "Thyroid Cancer,” Cancer Letters, 163, 2001, 143-156.
[4] L. Vini, and C. Harmer, "Management of Thyroid Cancer,” Lancet Oncology, 3, 2002, 407-14.
[5] C. Bomford, and I. Kunkler, Walter and Miller’s Textbook of Radiotherapy: radiation physics, therapy and oncology, Edinburgh: Churchill Livingstone, 2003.
[6] A. Shaha, and S. Patel, "Thyroid and Parathyroid Tumours,” in J. Shah, (eds) Cancer of the Head and Neck. London: Hamilton, 2001.
[7] E. Mazzaferri, and R. Kloos, "Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer,” The Journal of Clinical Endocrinology & Metabolism, 86, 2001, 1447-1463.
[8] M. Curado, B. Edwards, H. Shin et al., "Cancer Incidence in Five Continents, vol. 9 of IARC Scientific Publications,” No. 160, IARC, Lyon, France, 2007.
[9] B. Busnardo, D. De Vido, "The epidemiology and etiology of differentiated thyroid carcinoma,” Biomed & Pharmacother, 54, 2000, 322-6.
[10] T. McCarty, R. Vassilopoulou, & R. Lustig, "Thyroid and Parathyroid Cancers,” in R. Pazdur, L. Coia, W. Hoskins, et al., (eds), Cancer Management: A Multidisciplinary Approach. Medical, Surgical, & Radiation Oncology. New York: PRR Inc, 2001.
[11] L. Wartofsky, "Papillary Carcinoma: Clinical Aspects,” in L. Wartofsky, (eds.), Thyroid Cancer A comprehensive Guide to Clinical Management. New Jersey: Humana Press Inc, 2000.
[12] M. Schlumberger, "Papillary and Follicular Thyroid Carcinoma,” The New England Journal of Medicine, 338, 1998, 297-306.
[13] S. Moore, B. Haughey, "Surgical Treatment for Thyroid Cancer,” AORN, 65,1997, 710-725
[14] M. Kouvaraki, J. Lee, S. Shapiro, S. Sherman, & B. Douglas, "Preventable reoperations for persistent and recurrent papillary thyroid carcinoma,” Surgery, 136, 2004, 1183-91.
[15] L. Zimmer, B. Mccook, C. Meltzer, M. Fukui, D. Bascom, C. Snyderman, D. Townsend, and J. Johnson, "Combined Positron emission tomography/computed tomography imaging of recurrent thyroid cancer,” Otalaryngology-Head and Neck Surgery, 128, 2003, 178-84.
[16] H. Burch, "Papillary Thyroid Cancer: Prognosis,” in L. Wartofsky, (eds.), Thyroid Cancer A comprehensive Guide to Clinical Management. New Jersey: Humana Press Inc, 2000.
[17] J. Zidan, E. Hefer, G. Iosilevski, K. Drumea, M. Stein, A. Kuten, and O. Israel, "Efficacy of I131 Ablation Therapy using Different doses as determined by post operative thyroid scan uptake in patients with differentiated thyroid cancer,” Int J. Radiation Oncology Biol. Phys, 59, 2004, 1330-1336
[18] O. Clark, "Surgical Approach to Papillary Carcinoma,” in L. Wartofsky, (eds.), Thyroid Cancer A comprehensive Guide to Clinical Management. New Jersey, Humana Press Inc, 2000.
[19] N. Esnaola, S. Cantor, S. Sherman, J. Lee, and D. Evans, "Optimal treatment strategy in patients with papillary thyroid cancer: A decision analysis,” Surgery, 130, 2001, 921-30.
[20] A. Phillips, J. Fenwick, U. Mallick, and P. Perros, "The Impact of Clinical Guidelines on Surgical Management in Patients with Thyroid Cancer,” Clinical Oncology, 15, 2003, 485-489
[21] K. Chao, C. Perez, and L. Brady, (eds) Radiation Oncology Management Decisions. Philadelphia: Lippincott Williams & Wilkins, 2002.
[22] S. Chow, S. Law, W. Mendenhall, S. Au, P. Chan, T. Leung, C. Tong, I. Wong, and W. Lau, "Papillary Thyroid Carcinoma: Prognostic Factors and the role of Radioiodine and External Radiotherapy,” Int J. Radiation Oncology Biol. Phys, 52, 2002, 784-795
[23] R. Mazzarotto, M. Cesaro, O. Lora, D. Rubello, D. Casara, and G. Sotti, "The role of external beam radiotherapy in the management of differentiated thyroid cancer,” Biomed & Pharmacother, 54, 2000, 345- 9
[24] D. Cooper, G. Doherty, B. Haugen, R. Kloos, S. Lee, S. Mandel et al., "Revised America Thyroid Association Management Guidlelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer,” Thyroid, 19, 2009, 1-48.
[25] D. Ford, S. Giridharan, C. McConkey., A. Hartley, C. Brammer, J. Watkinson, et al., "External Beam Radiotherapy in the Management of Differentiated Thyroid Cancer,” Clinical Oncology, 15, 2003, 337-341.
[26] M. Bauman, M. Saunders, and M. Joiner, "Modified Fractionation,” in G. Steel, (eds), Basic Clinical Radiobiology. London: Arnold, 2002.
[27] C. Nutting, D. Convery, V. Cosgrove, C. Rowbottom, V. Louiza., C. Harmer, D. Dearnley, and S. Webb S., "Improvements in target Coverage and reduced spinal cord irradiation using Intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland,” Radiotherapy and Oncology, 60, 2001, 173-180
[28] R. White, (2000) ‘Management of Papillary Thyroid Carcinoma: External Radiation Therapy’ in L. Wartofsky, (ed.), Thyroid Cancer. A comprehensive Guide to Clinical Management. New Jersey: Humana Press Inc, 2000.
[29] P. Wilson, B. Millar, and Brierley, "The Management of Advanced Thyroid Cancer,” Clinical Oncology, 16, 2004, 561-568.
[30] T. Kim, D. Yang, K. Jung, C. Kim, and M. Choi M., "Value of External Irradiation for Locally Advanced Papillary Thyroid Cancer,” International. Journal of Radiation Oncology Biology. Physics, 55, 2003, 1006-1012.